Zealand Pharma's peptide-based therapy dasiglucagon Phase 3 clinical trial reaches primary and secondary end points of trial

today, The http://of The Peptide-based Therapy developed by
The Company has reached the primary end and all critical secondary endpoints in the validation of the Phase 3 ClinicalTrial(http://for the treatment of severe hypoglycemia symptoms in diabetic patientsDasiglucagon is a potential "first-in-class" soluble glucagon analogueDasiglucagon is a glucagon analogue developed by Zealand, which has a unique stability and can be stable in the state of aqueous solutionZealand has also developed an auto-injector called HypoPal, which can be operated by diabetics themselves to quickly treat severe hypoglycemiaIn this Phase 3 clinical trial, 45 people with type 1 diabetes participated in the trialThe results showed that after insulin-induced hypoglycemia, a single injection of dasiglucagon with HypoPal was able to begin to restore blood sugar levels within 10 minutes, significantly better than placebo (35 minutes, p0.001), Zealand is currently conducting a Phase 3 clinical trial to test the efficacy of dasiglucagon in pediatric diabeticsThe company is expected to get the results of the clinical trial in September and submit aapplication for new drug(http://to the u.SFDA(http://early next year